Every step along the immuno-oncology drug discovery continuum reveals unique insights that inform, predict, and progress immunotherapies, in vitro to in vivo and ultimately to the clinic. Learn more about our platform
Publication Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD) Learn More
Publication Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis Learn More
Product/Service Material 3D Engineered Hydrogel Oncology and Immuno-Oncology Assays Using the Cypre Falcon-X™ Platform Learn More
